Company Overview
Company Type: Public Company
Website: www.profoundmedical.com
Number of Employees: 131
Ticker: PRN (TSX)
Year Founded: -


Business Description
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, palliative pain treatment of bone metastases, and osteoid osteoma. Profound Medical Corp. is headquartered in Mississauga, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
9.2
Market Capitalization
282.3
TEV/Total Revenue
26.0x
EBITDA
(37.6)
Total Enterprise Value
241.3
TEV/EBITDA
NM
EBIT
(38.0)
Cash & ST Invst.
53.7
P/Diluted EPS Before Extra
NM
Net Income
(39.1)
Total Debt
11.3
Price/Tang BV
4.7x
Total Assets
77.7
Total Debt/EBITDA
NM


Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-05-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS Normalized
(0.44)
(0.42)
(1.82)
(1.50)
(1.70)
Revenue (mm)
2.82
3.53
11.06
20.56
14.96
EBITDA (mm)
(8.07)
(7.43)
(30.09)
(25.76)
(29.56)

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
22.56x
TEV/EBITDA
NM
P/BV
7.72x

Non-Periodic Estimates

Recommendation
Outperform (1.63)


Key Professionals
Name
Title
Menawat, Arun Swarup
Chairman of the Board & CEO
Dewan, Rashed 
Chief Financial Officer
Kilmer, Stephen 
Investor Relations
Burtnyk, Mathieu 
Senior Vice President of Product Leader TULSA-PRO
Cornet, Jacques F.
Senior VP & Product Leader Sonalleve
Goodman, Abbey 
Chief Commercial Officer of US
Warnken, Hartmut 
Chief Commercial Officer of Outside US
Sobczyk, Matthew 
Assistant Corporate Controller
Tinaz, Levant 
Software Developer

Key Board Members
Name
Title
Menawat, Arun Swarup
Chairman of the Board & CEO
Lortie, Murielle 
Independent Director
Rosenthal, Arthur L. J.
Independent Director
Ellacott, Brian R.
Independent Lead Director
Eggener, Scott 
Member of Clinical Advisory Board
Emberton, Mark 
Member of Clinical Advisory Board
Ghanouni, Pejman 
Member of Clinical Advisory Board
Kella, Naveen 
Member of Clinical Advisory Board
Kibel, Adam 
Member of Clinical Advisory Board
Klein, Eric A.
Member of Clinical Advisory Board
Klotz, Laurence 
Member of Clinical Advisory Board
Lavoie, Cynthia 
Independent Director


Primary Industry Classification
Health Care Equipment


Primary Office Location
2400 Skymark Avenue Unit 6 | Mississauga, ON | L4W 5K5 | Canada
Phone: 647 476 1350   Fax: 647 847 3739

Current and Pending Investors
Amplitude Ventures, BDC Capital Inc., CTI Life Sciences, Federal Economic Development Agency for Southern Ontario, Genesys Capital Partners Inc. (Damian Lamb), JJR Capital Corp., Investment Arm, Knight Therapeutics Inc. (TSX:GUD), MaRs Discovery District, Investment Arm, Ontario Centres of Excellence, Inc., Investment Arm

Prior Investors
Fight Against Cancer Innovation Trust, Investment Arm, The Health Technology Exchange

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 13.60
Market Cap (mm)
290.6
Open
 13.01
Shares Out. (mm)
21.4
Previous Close
 13.60
Float %
84.6%
Change on Day
0.33
Shares Sold Short (mm)
-
Change % on Day
2.5%
Dividend Yield %
-
Day High/Low
 13.60/ 13.01
Diluted EPS Excl. Extra Items
(1.87)
52 wk High/Low
 20.44/ 4.21
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0030
Avg 3M Dly Vlm (mm)
0.0064
Beta 5Y
1.09


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
TSX:PRN - Common Stock


Index Membership
S&P/TSX SmallCap Index;S&P/TSX Smallcap Index - Health Care (Sector);S&P/TSX Smallcap Index - Health Care Equipment & Services (Industry Group);S&P/TSX Smallcap Index - Health Care Equipment & Supplies (Industry);S&P/TSX Smallcap Index - Health Care Equipment (Sub Industry)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Wing Medical Oy
Koninklijke Philips N.V., Sonalleve MR-HIFU Business comprises therapeutic platform with real-time MR imaging and thermometry with thermal ultrasound. As of July 31, 2017, Wing Medical Oy operates as a subsidiary of Profound Medical Corp.

Europe
Health Care Equipment
-
-
-
Mira IV Acquisition Corp.
As of June 4, 2015, Mira IV Acquisition Corp. was acquired by Profound Medical Inc., in a reverse merger transaction. Mira IV Acquisition Corp. is a blank check company. The company is based in Toronto, Canada.

United States and Canada
Asset Management and Custody Banks
-
1.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-6-2023
-
Public Offering
Target
Profound Medical Corp. (TSX:PRN)


30.00
Mar-3-2022
-
Shelf Registration
Target
Profound Medical Corp. (TSX:PRN)


100.00
Jul-15-2020
Jul-15-2020
Public Offering
Target
Profound Medical Corp. (TSX:PRN)


40.00
May-20-2020
-
Shelf Registration
Target
Profound Medical Corp. (TSX:PRN)


14.28
Jan-21-2020
Jan-22-2020
Public Offering
Target
Profound Medical Corp. (TSX:PRN)


34.37
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-26-2023
Company Conference Presentations
Profound Medical Corp. Presents at Cantor Fitzgerald Annual Global Healthcare Conference 2023, Sep-26-2023 04:55 PM
Sep-25-2023
Product-Related Announcements
Profound Medical Corp. Receives U.S. FDA 510(k) Clearance for TULSA-PRO Thermal Boost
Sep-18-2023
Index Constituent Drops
Profound Medical Corp.(TSX:PRN) dropped from S&P Global BMI Index
Sep-06-2023
Follow-on Equity Offerings
Profound Medical Corp. has filed a Follow-on Equity Offering in the amount of $30 million.
Aug-09-2023
Earnings Calls
Profound Medical Corp., Q2 2023 Earnings Call, Aug 09, 2023

Competitors
EDAP TMS S.A. (NasdaqGM:EDAP), INSIGHTEC Ltd., SonaCare Medical, LLC

M&A Advisors
Osler, Hoskin & Harcourt LLP, Torys LLP


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
M&A Advisors
Osler, Hoskin & Harcourt LLP, Torys LLP
Private Placement Advisors
Bloom Burton & Co. Inc., CIBC World Markets, Inc., Cormark Securities Inc., Research Capital Corporation, RF Securities Clearing LP
Public Offering Advisors
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Montgomery, Barnett, Brown, Read, Hammond & Mintz, LLP, Osler, Hoskin & Harcourt LLP, PricewaterhouseCoopers LLP, PricewaterhouseCoopers LLP, Canada, Torys LLP


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 04:02 AM
PRN
Profound Medical Corp 2023_10_05
Reports
14
ValuEngine, Inc.

Oct 02, 2023 06:34 AM
PRN
ValuEngine - Toronto Quantitative Stock Report for PRN
Reports
9
ValuEngine, Inc.

Oct 02, 2023 05:16 AM
PRN
ValuEngine Rating and Forecast Report for PROF
Reports
11
The Economy Matters

Oct 02, 2023 04:22 AM
PRN
The Economy Matters
Reports
8
CFRA Equity Research

Oct 01, 2023 11:13 AM
PRN
Profound Medical Corp.
Reports
9
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Sep 19, 2023 06:00 PM
PRN
Will Profound Medical Corp Continue its Slide?
Ratings Change*
12
Raymond James Ltd.
Sarugaser, Rahul
Sep 18, 2023 05:05 AM
PRN
PROF | ↑Strong Buy | ~1H24 Pricing-in of 2025 CPT-Driven Sales Inflection | Mapping PRCT onto PROF
EPS Estimates*
10
GlobalData

Sep 15, 2023 10:47 AM
PRN
Profound Medical Inc - Medical Devices Product Pipeline Summary
Reports
72
GlobalData

Sep 14, 2023 07:12 PM
PRN
Profound Medical Inc
Reports
156
S&P Global Compustat

Sep 07, 2023 03:58 AM
PRN
Profound Medical Corp 2023_09_07
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Gagnon Securities, LLC

1,605,140

7.51

20.7

Jun-30-2023


FMR LLC

1,265,050

5.92

16.3

Dec-30-2022


Fidelity International Ltd

1,200,635

5.62

15.5

Jun-30-2023


Letko, Brosseau & Associates Inc.

1,168,275

5.47

15.1

Jun-30-2023


Gagnon, Neil Joseph

1,121,431

5.25

14.5

Apr-06-2023


Timelo Investment Management Inc.

731,658

3.42

9.5

Jun-30-2023


Gagnon Advisors, LLC

679,296

3.18

8.8

Jun-30-2023


Raymond James Financial Services Advisors, Inc.

581,236

2.72

7.5

Jun-30-2023


Royce & Associates, LP

565,998

2.65

7.3

Jun-30-2023


Menawat MBA, Ph.D., Arun Swarup

425,296

1.99

5.5

Apr-06-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Raymond James Financial Services Advisors, Inc.
581,236
68,533
Gagnon Advisors, LLC
679,296
30,831
Goldman Sachs Group, Investment Banking and Securities Investments
16,700
16,700
Fidelity International Ltd
1,200,635
13,010
Citadel Advisors LLC
12,194
12,194

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Gagnon Securities, LLC
1,605,140
(115,424)
Zweig-DiMenna Associates, Inc.
124,579
(86,196)
North Growth Management Ltd.
122,000
(34,000)
Timelo Investment Management Inc.
731,658
(24,521)
BMO Asset Management Corp.
12,071
(22,720)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Novel Ablation Devices, Sonalleve System, TULSA-PRO System


Upcoming Events
Date/Time
Type
Oct-13-2023
Analyst/Investor Day
Nov-03-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-25-2023
-
Profound Medical Corp. (TSX:PRN)
SEDAR
News Releases
29 KB
Sep-25-2023
-
Profound Medical Corp. (TSX:PRN)
SEDAR
News Releases
29 KB
Sep-25-2023
-
Profound Medical Corp. (TSX:PRN)
SEDAR
News Releases
29 KB
Sep-25-2023
Sep-25-2023
Profound Medical Corp. (TSX:PRN)
SEC
6-K
14 KB
Sep-21-2023
-
Profound Medical Corp. (TSX:PRN)
SEDAR
News Releases
18 KB
Sep-21-2023
Sep-21-2023
Profound Medical Corp. (TSX:PRN)
SEC
6-K
10 KB
Sep-19-2023
-
Profound Medical Corp. (TSX:PRN)
SEDAR
News Releases
16 KB
Sep-19-2023
Sep-19-2023
Profound Medical Corp. (TSX:PRN)
SEC
6-K
9 KB
Sep-07-2023
Sep-06-2023
Profound Medical Corp. (TSX:PRN)
SEC
6-K
16 KB
Sep-07-2023
Sep-06-2023
Profound Medical Corp. (TSX:PRN)
SEC
6-K
367 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Menawat MBA, Ph.D., Arun Swarup (Chairman of the Board & CEO)
Dec-20-2022
Common Shares
13,000
138,810
Open Market Acquisition
3.15
Multiple
Knudson, Kenneth  (Former Chief Commercial Officer)
Sep-07-2022
Common Shares
5,000
38,229
Open Market Acquisition
28.25
Multiple
Knudson, Kenneth  (Former Chief Commercial Officer)
Jun-29-2022
Common Shares
3,000
28,682
Open Market Acquisition
20.41
Multiple
Knudson, Kenneth  (Former Chief Commercial Officer)
Jun-14-2022
Common Shares
2,500
25,851
Open Market Acquisition
20.49
Multiple
Rosenthal Ph.D., Arthur L. J. (Independent Director)
May-31-2022 - Jun-02-2022
Common Shares
10,800
133,938
Open Market Acquisition
166.15
Multiple
-
Jun-01-2022
Common Shares
500
6,305
Open Market Acquisition
-
Exchange Announcement
-
May-31-2022
Common Shares
6,762
84,017
Open Market Acquisition
-
Exchange Announcement
-
Jun-02-2022
Common Shares
538
6,978
Open Market Acquisition
-
Exchange Announcement
-
Jun-01-2022
Common Shares
3,000
36,637
Open Market Acquisition
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Menawat, Arun Swarup
Chairman of the Board & CEO
(905) 629-3822
647 847 3739
amenawat@profoundmedical.com
Lortie, Murielle 
Independent Director
647 476 1350
647 847 3739

Rosenthal, Arthur L. J.
Independent Director
647 476 1350
647 847 3739
arosenthal@adventinternational.com
Ellacott, Brian R.
Independent Lead Director
647 476 1350
647 847 3739

Eggener, Scott 
Member of Clinical Advisory Board
647 476 1350
647 847 3739

Emberton, Mark 
Member of Clinical Advisory Board
647 476 1350
647 847 3739

Ghanouni, Pejman 
Member of Clinical Advisory Board
647 476 1350
647 847 3739

Kella, Naveen 
Member of Clinical Advisory Board
647 476 1350
647 847 3739

Kibel, Adam 
Member of Clinical Advisory Board
647 476 1350
647 847 3739

Klein, Eric A.
Member of Clinical Advisory Board
647 476 1350
647 847 3739

Klotz, Laurence 
Member of Clinical Advisory Board
647 476 1350
647 847 3739

Lavoie, Cynthia 
Independent Director
647 476 1350
647 847 3739

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Menawat, Arun Swarup
Chairman of the Board & CEO
(905) 629-3822
647 847 3739
amenawat@profoundmedical.com
Dewan, Rashed 
Chief Financial Officer
647 476 1350
647 847 3739

Kilmer, Stephen 
Investor Relations
647.872.4849
647 847 3739
skilmer@profoundmedical.com
Burtnyk, Mathieu 
Senior Vice President of Product Leader TULSA-PRO
647 476 1350
647 847 3739

Cornet, Jacques F.
Senior VP & Product Leader Sonalleve
647 476 1350
647 847 3739

Goodman, Abbey 
Chief Commercial Officer of US
647 476 1350
647 847 3739

Warnken, Hartmut 
Chief Commercial Officer of Outside US
647 476 1350
647 847 3739

Sobczyk, Matthew 
Assistant Corporate Controller
647 476 1350
647 847 3739

Tinaz, Levant 
Software Developer
647 476 1350
647 847 3739

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
